⚕ GalenOps field
←

SITE006-0003

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-02-11

AEs
8
Serious
1
Dropout signal
–

Adverse events

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-15 (study day 409); relationship: N

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-07-19 (study day 504); relationship: not assessed

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-09-15 (study day 562); relationship: not assessed

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-10-11 (study day 588); relationship: N

severe serious assessed

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-16 (study day 593); relationship: not assessed; serious criteria: life-threatening

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-12-09 (study day 647); relationship: N

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-02-03 (study day 703); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-04-09 (study day 769); relationship: not assessed

Data queries

No data queries.